Period:
Draw Mode:
| Volume | 103,848 |
|
|||||
| News | - | ||||||
| Day High | 1.848 | Low High |
|||||
| Day Low | 1.7511 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0861 | -4.68% | 1.7539 | 15:07:42 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.76 | 1.7511 | 1.848 | 1.84 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 562 | 103,848 | $ 1.78 | $ 185,366 | - | 0.6706 - 6.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:07:42 | 600 | $ 1.7539 | USD |
Marker Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 15.43M | 8.80M | 6.06M | $ - | $ - | -0.57 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | - |
Marker Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.30 | 1.95 | 1.21 | 1.78 | 10,091,337 | 0.4539 | 34.92% |
| 1 Month | 1.42 | 1.95 | 1.16 | 1.77 | 2,159,790 | 0.3339 | 23.51% |
| 3 Months | 1.89 | 2.00 | 0.6706 | 1.66 | 845,354 | -0.1361 | -7.2% |
| 6 Months | 2.90 | 4.3645 | 0.6706 | 1.96 | 491,120 | -1.15 | -39.52% |
| 1 Year | 3.20 | 6.60 | 0.6706 | 3.90 | 808,009 | -1.45 | -45.19% |
| 3 Years | 22.30 | 37.70 | 0.6706 | 15.73 | 908,081 | -20.55 | -92.13% |
| 5 Years | 100.10 | 102.50 | 0.6706 | 21.93 | 725,565 | -98.35 | -98.25% |
Marker Therapeutics Description
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |